Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-25
2006-07-25
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S418000, C548S483000, C548S484000, C548S486000
Reexamination Certificate
active
07081470
ABSTRACT:
This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 4874687 (1989-10-01), Itabashi et al.
patent: 4921503 (1990-05-01), Anderson et al.
patent: 4946956 (1990-08-01), Wheeler et al.
patent: 5017466 (1991-05-01), Kobayashi et al.
patent: 5198461 (1993-03-01), Watjen et al.
patent: 5547949 (1996-08-01), Maho et al.
patent: 5728704 (1998-03-01), Mylari et al.
patent: 5801150 (1998-09-01), Caillot et al.
patent: 5840893 (1998-11-01), Bukrinsky et al.
patent: 6287788 (2001-09-01), Bard et al.
patent: 6329197 (2001-12-01), Bard et al.
patent: 6368812 (2002-04-01), Bard et al.
patent: 2003/0082641 (2003-05-01), Bard et al.
patent: 2003/0119096 (2003-06-01), Bard et al.
patent: 2004/0127502 (2004-07-01), Blackburn et al.
patent: 0 359 465 (1990-03-01), None
patent: 0 363 002 (1990-04-01), None
patent: 0 640 599 (1995-03-01), None
patent: 0 667 340 (1995-08-01), None
patent: 0 788 890 (1997-08-01), None
patent: 0 945 442 (1999-09-01), None
patent: 0 972 770 (2000-01-01), None
patent: 1477349 (2000-06-01), None
patent: 11158073 (1999-06-01), None
patent: 2000075449 (2000-03-01), None
patent: WO 99/41253 (1999-08-01), None
patent: WO 99/50250 (1999-10-01), None
patent: WO 93/25539 (1999-12-01), None
patent: WO 99/65875 (1999-12-01), None
patent: WO 00/02865 (2000-01-01), None
U.S. Appl. No. 10/638,242 by Konkel, Blackburn and Wetzel.
U.S. Appl. No. 10/066,175, especially claim 222 and paragraph 1624.
U.S. Appl. No. 10/066,175, filed Jan. 31, 2002, Blackburn et al.
U.S. Appl. No. 10/214,873, filed Aug. 7, 2002, Konkel et al.
Hokfelt, T., et al., Galanin and NPY, Two Peptides with Multiple Putative Roles in the Nervous System,Horm. Metab. Res., (1999), 33:330-334.
Razani, H., et al., Intraventricular Galanin Produces a Time-Dependent Modulation of 5-HT1AReceptors in the Dorsal Raphe of the Rat,Neuropharmacology and Meurotoxicology, (2000), 11(18): 3943-3948.
Chemical Abstracts Registry No. 61038-64-0.
Chemical Abstracts Registry No. 41230-77-7.
Chemical Abstracts Registry No. 130186-15-1.
Chemical Abstracts Registry No. 130186-16-2.
Chemical Abstracts Registry No. 130186-17-3.
Chemical Abstracts Registry No. 130186-18-4.
Chemical Abstracts Registry No. 130186-21-9.
Chemical Abstracts Registry No. 130270-13-2.
Chemical Abstracts Registry No. 133939-75-0.
Chemical Abstracts Registry No. 56984-58-8.
Chemical Abstracts Registry No. 77910-42-0.
Chemical Abstracts Registry No. 70010-41-2.
Chemical Abstracts Registry No. 189264-35-5.
Chemical Abstracts Registry No. 88291-07-0.
Chemical Abstracts Registry No. 154118-05-5.
Chemical Abstracts Registry No. 155717-81-0.
Chemical Abstracts Registry No. 159967-24-5.
Chemical Abstracts Registry No. 138601-94-2.
Chemical Abstracts Registry No. 136647-69-3.
Chemical Abstracts Registry No. 136647-72-8.
Chemical Abstracts Registry No. 77297-28-0.
Chemical Abstracts Registry No. 43002-26-2.
Chemical Abstracts Registry No. 303954-69-2.
Chemical Abstracts Registry No. 122725-53-5.
Chemical Abstracts Registry No. 122803-89-8.
Chemical Abstracts Registry No. 303149-10-2.
Chemical Abstracts Registry No. 303149-08-8.
Chemical Abstracts Registry No. 303149-06-6.
Chemical Abstracts Registry No. 303984-47-6.
Chemical Abstracts Registry No. 303149-14-6.
Chemical Abstracts Registry No. 303149-12-4.
Chemical Abstracts Registry No. 303984-51-2.
Chemical Abstracts Registry No. 303984-49-8.
Chemical Abstracts Registry No. 303954-48-7.
Chemical Abstracts Registry No. 303984-52-3.
Chemical Abstracts Registry No. 303984-60-3.
Chemical Abstracts Registry No. 303984-61-4.
Chemical Abstracts Registry No. 303984-62-5; and.
Chemical Abstracts Registry No. 303984-68-1.
Konkel Michael
Talisman Jamie
Werzel John M.
Chung Susannah L.
H. Lundbeck A/S
Lowenstein & Sandler PC
Saeed Kamal A.
LandOfFree
Use of GALR3 receptor antagonists for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of GALR3 receptor antagonists for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of GALR3 receptor antagonists for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3563976